Grants and Stock Movements of Major Drug Manufacturers - Research Report on AbbVie, Keryx Biopharmaceuticals, Pacira Pharmaceuticals, Rockwell Medical, and Impax Laboratories Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 22, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting AbbVie Inc. (NYSE: ABBV), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Rockwell Medical Inc. (NASDAQ: RMTI), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AbbVie Inc. Research Report
On November 18, 2013, AbbVie Inc. (AbbVie), along with the North Chicago public schools, announced a grant of $350,000 for math education. According to the Company, the grant will enable educators to strengthen and reinforce the math curriculum for students (K-8) within the district and assist in the implementation of an engaging, common core aligned curriculum designed to increase both educator and student understanding of mathematics as well as proficiency in mathematics. In a release published on the same date, the Company also reported the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). AbbVie further stated that patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR12) of 96%, during the 631-patient SAPPHIRE-I study. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Keryx Biopharmaceuticals Inc. Research Report
On November 19, 2013, Keryx Biopharmaceuticals Inc.'s (Keryx) stock decreased by 1.47% to $12.40 per share. The Company's stock went down by 1.59% over the previous three trading days, compared to the Nasdaq Composite which also went down by 1.04% during the same period. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Pacira Pharmaceuticals Inc. Research Report
On November 19, 2013, Pacira Pharmaceuticals Inc.'s (Pacira Pharmaceuticals) stock was down by 1.15%, closing the day at $54.31 per share. Over the past three trading sessions, the Company's stock went down by 0.86%, compared to the Dow Jones Industrial Average which went up by 0.57% during the same period. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Rockwell Medical Inc. Research Report
On November 19, 2013, Rockwell Medical Inc.'s (Rockwell Medical), formerly known as Rockwell Medical Technologies Inc., stock went down by 0.34% closing the trading day at $14.62 per share. Additionally, over the past three trading days, the Company's stock reflected an increase of 4.28%, compared to the Nasdaq Composite which in turn reflected a decrease of 1.04% within the same trading period. The Full Research Report on Rockwell Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Impax Laboratories Inc. Research Report
On November 19, 2013, Impax Laboratories Inc.'s (Impax Laboratories) stock decreased by 0.13% as it closed the day with $22.82 per share. The Company's stock also reflected a decline over the past three trading days at 1.38%, compared to the Dow Jones Industrial Average which increased by 0.57% within the same trading period. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner